Zobrazeno 1 - 10
of 146
pro vyhledávání: '"R. Oberneder"'
Autor:
F. Albert, A. Antoniewicz, T. Grantzow, A. Greis, G. Fingerle-Rowson, P. Ruf, H. Lindhofer, M. Kriegmair, R. Oberneder
Publikováno v:
European Urology Open Science. 45:S234-S235
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::500d8c758937cc3f442d02097be29057
https://doi.org/10.1016/s2666-1683(22)02578-2
https://doi.org/10.1016/s2666-1683(22)02578-2
Autor:
Marie-Claire Rassweiler-Seyfried, Frederik Wessels, M.C. Kriegmair, R. Oberneder, A. Oehme, Maurice-Stephan Michel, Philipp Erben, Manuel Ritter, P. Honeck, Maximilian C. Kriegmair
Publikováno v:
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 45(7)
Introduction Aim of this study was to analyse the perioperative outcome of patients undergoing radical cystectomy under continuous antiplatelet therapy with acetylsalicylic acid. Materials and methods Using prospectively maintained databases of two d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab6011d2c6b409c30aea6ccd45eaec75
https://pubmed.ncbi.nlm.nih.gov/33131401
https://pubmed.ncbi.nlm.nih.gov/33131401
Autor:
H. Heinzer, R. Oberneder, Christian Doehn, Z. Varga, A. Hegele, Deutsche Gesellschaft für Immun und Targeted Therapie e.V., M. Siebels
Publikováno v:
Der Urologe. 50:1110-1117
Seit 2006 wurden fur die Behandlung des metastasierten Nierenzellkarzinoms (mNZK) 6 neue Substanzen in Deutschland zugelassen. Vergleichende Studien zum Einsatz bei gleicher Indikation fehlen, die Reihenfolge einer potentiellen Sequenztherapie ist bi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::54c4157660ec03d26ad9f32b4a59d335
https://doi.org/10.1007/s00120-011-2553-3
https://doi.org/10.1007/s00120-011-2553-3
Autor:
R. Oberneder, Patrick Honeck, T. Bocklitz, Thomas Knoll, G. Hipp, A. Stenzl, N. Ali, J. Popp, Tilman Todenhöfer, A. Hartmann, Maximilian C. Kriegmair
Publikováno v:
European Urology Supplements. 17:e1241
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::95703932f504872916050374c57be475
https://doi.org/10.1016/s1569-9056(18)31710-x
https://doi.org/10.1016/s1569-9056(18)31710-x
Publikováno v:
European Journal of Cancer. 92:S1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::59b6bd98aee1dd5837ef0d866ef09fc1
https://doi.org/10.1016/j.ejca.2018.01.005
https://doi.org/10.1016/j.ejca.2018.01.005
Publikováno v:
Aktuelle Urologie. 41:122-130
INTRODUCTION: Until recently, the standard therapy for metastatic renal cell carcinoma (mRCC) in Germany consisted of interleukin-2 (IL-2), inter-feron-alfa (IFN) as single agents or in combina-tion, with or without chemotherapy. Since 2005, new drug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed6174bcb3fad7219f270fe0aacf14b3
https://doi.org/10.1055/s-0029-1224676
https://doi.org/10.1055/s-0029-1224676
Autor:
M. Vogesser, R. Oberneder, Eckhart Dühmke, Moshe Schaffer, Alfons Hofstetter, P. M. Schaffer, Giulio Jori, Birgit Ertl-Wagner, J. Rauch
Publikováno v:
Photochemical & Photobiological Sciences. 1:686-689
Background: the effect of ionizing radiation on tumour tissues can be optimised by adding radiosensitising agents to enhance tumour inactivation. Photofrin II has been approved as a photosensitising agent for the photodynamic therapy (PDT) of selecte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c13b29812972ed2456ca223b2c086ea8
https://doi.org/10.1039/b203732g
https://doi.org/10.1039/b203732g
Autor:
K. Schmidt, M. Baier, Reinhard Andreesen, S. Feyerabend, Katrin Birkholz, R. Oberneder, W. F. Wieland, A. Bakhshandeh-Bath, A. Ruebel, S. Mueller, Wolfgang Herr, H. Heinzer, Albrecht Reichle, Arnulf Stenzl, T. Suedhoff, F. Eichhorn, J. Huebner, Martin Vogelhuber, M. Schulze
Publikováno v:
Cancer Microenvironment
Therapeutic options for patients with castration-resistant prostate cancer (CRPC) remain limited. In a multicenter, Phase II study, 65 patients with histologically confirmed CRPC received a biomodulatory regimen during the six-month core study. Treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5242a29c4446cdf6e938ed777e0d667f
https://pubmed.ncbi.nlm.nih.gov/25651886
https://pubmed.ncbi.nlm.nih.gov/25651886
Publikováno v:
LaboratoriumsMedizin. 25:337-342
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::69d465f88f9acc140f5dea7cb9d4c82c
https://doi.org/10.1515/labm.2001.25.9-10.337
https://doi.org/10.1515/labm.2001.25.9-10.337
Publikováno v:
Endocrine Research. 25:281-293
Although it is known that growth hormone (GH) exerts its growth-promoting effects mainly via Insulin-like growth factor-I (IGF-I), an increasing number of direct effects of GH has been described in many tissues. In vivo, mice transgenic for human gro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a80e7cd8de463b6e0d6ba58a78b5fa1c
https://doi.org/10.1080/07435809909066148
https://doi.org/10.1080/07435809909066148